Donald Trump's Tylenol Alert Turns Kenvue Stock (KVUE) into a Hidden Opportunity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 08 2025
0mins
Should l Buy KVUE?
Source: TipRanks
Kenvue Stock Decline: Shares of Kenvue (KVUE) have dropped 25% over six months following claims linking Tylenol use during pregnancy to autism, despite the company and health experts asserting no credible evidence supports this claim.
Investment Opportunity: The stock's current valuation at 15.3x 2025 earnings estimates presents a buying opportunity for investors, especially given Kenvue's strong portfolio of trusted brands and a dividend yield of over 5%, which is significantly higher than the S&P 500 average.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 16.730
Low
17.00
Averages
18.86
High
23.00
Current: 16.730
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Jim Cramer's Charitable Trust Adjusts Portfolio with J&J and BMY Trades
- Exit from Bristol Myers: Jim Cramer's Charitable Trust sold 1,100 shares of Bristol Myers at approximately $58.94, maintaining a small gain of 3.5%, but opted to exit due to concerns over pharmaceutical tariffs and a failed clinical trial, thereby mitigating potential losses.
- Initiation of Johnson & Johnson Position: Concurrently, the Trust initiated a new position in Johnson & Johnson by purchasing 150 shares at roughly $237.65, which will represent about 1% of the portfolio, reflecting confidence in J&J's long-term growth potential, particularly in its innovative medicines and medical products segments.
- Sales Growth at Johnson & Johnson: Johnson & Johnson generated approximately $94 billion in sales in 2025, with about two-thirds from its pharmaceutical division, particularly strong in oncology, where sales are expected to exceed $50 billion annually by 2030, showcasing its competitive edge in the market.
- Legal Risk Mitigation: Johnson & Johnson has adjusted its legal strategy regarding the baby powder lawsuits, moving away from blanket settlements to address cases individually, which has significantly reduced overall legal risks and provided greater upside potential for its stock price.
See More
Analysis of Declining Stocks: Nike, Kimberly-Clark, and Conagra Brands
- Nike's Price Plunge: Nike's stock has fallen nearly 70% over the past five years, currently trading at $43.49 with a market cap of $63 billion, facing significant headwinds from foreign competition, the rise of fast fashion, and inflation; despite efforts by the new CEO to focus on in-store sales, results have been disappointing, leaving future growth uncertain.
- Kimberly-Clark's Acquisition Concerns: Kimberly-Clark's shares have dropped over 30% in five years, now priced at $96.05 with a market cap of $31 billion; the announcement of a nearly $49 billion acquisition of Kenvue has rattled investors, as it could enhance its position in global health and wellness but also increases risk significantly.
- Conagra Brands' Major Challenges: Conagra's stock has declined nearly 60% in five years, currently at $15.56 with a market cap of $7.4 billion, struggling with growth due to factors like GLP-1 drugs reducing consumer appetites, rising food costs, and high oil prices, leading to a 1.9% drop in Q3 sales, casting a shadow over future prospects.
- Sustainability of High Dividend: Conagra offers a high dividend yield of 9.04%, but concerns about its sustainability arise due to low margins; while its forward P/E ratio is under nine, indicating attractive valuation, the lack of growth potential makes it a risky investment choice.
See More
Nike, Kimberly-Clark, and Conagra Stocks Plummet Over 30%
- Nike's Stock Plunge: Nike's share price has fallen nearly 70% over the past five years, reaching its lowest point since 2014, primarily due to rising international competition, the popularity of fast fashion, and inflation, which have created significant growth challenges for the company.
- Kimberly-Clark's Acquisition Concerns: Kimberly-Clark's stock has dropped over 30% in five years, with its announcement of a nearly $49 billion acquisition of Kenvue rattling investors; while this deal could enhance its position in the global health and wellness sector, it also increases the risk associated with what was previously considered a stable investment.
- Conagra Brands' Struggles: Conagra's shares have declined nearly 60% over five years, hitting levels not seen since 2009, largely due to the impact of GLP-1 drugs on consumer appetites, rising food costs, and elevated oil prices, all contributing to the company's inability to generate growth.
- Dividend Sustainability in Question: Despite Conagra's high dividend yield of around 9%, concerns about the sustainability of this payout are growing due to light margins, leading investors to speculate that a dividend cut may be inevitable, which could further undermine investor confidence.
See More
Johnson & Johnson Stock Supported by Strong Financials
- Strong Financial Performance: Johnson & Johnson reported revenue of $94.2 billion in 2025, a 6% increase, with earnings per share (EPS) reaching $11.03, up 90.5%, reflecting significant profitability improvement post-Kenvue spinoff.
- Consistent Dividend Growth: The company has raised its dividend for 63 consecutive years, with the latest 4.8% increase bringing the quarterly payout to $1.30 per share, resulting in a current yield of approximately 2.1%, bolstering investor confidence in its stock.
- Leading R&D Investment: Johnson & Johnson invested $14.6 billion in research and development last year, achieving 51 drug approvals and launching 15 new med-tech products, underscoring its leadership and innovation in the pharmaceutical sector.
- Existing Risks: Despite strong financials, Johnson & Johnson faces tens of thousands of lawsuits and pricing pressures from the Inflation Reduction Act, which could impact its future profit margins.
See More
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Jim Cramer's Charitable Trust Adjusts Portfolio with J&J and BMY Trades
- Exit from Bristol Myers: Jim Cramer's Charitable Trust sold 1,100 shares of Bristol Myers at approximately $58.94, maintaining a small gain of 3.5%, but opted to exit due to concerns over pharmaceutical tariffs and a failed clinical trial, thereby mitigating potential losses.
- Initiation of Johnson & Johnson Position: Concurrently, the Trust initiated a new position in Johnson & Johnson by purchasing 150 shares at roughly $237.65, which will represent about 1% of the portfolio, reflecting confidence in J&J's long-term growth potential, particularly in its innovative medicines and medical products segments.
- Sales Growth at Johnson & Johnson: Johnson & Johnson generated approximately $94 billion in sales in 2025, with about two-thirds from its pharmaceutical division, particularly strong in oncology, where sales are expected to exceed $50 billion annually by 2030, showcasing its competitive edge in the market.
- Legal Risk Mitigation: Johnson & Johnson has adjusted its legal strategy regarding the baby powder lawsuits, moving away from blanket settlements to address cases individually, which has significantly reduced overall legal risks and provided greater upside potential for its stock price.
See More
Analysis of Declining Stocks: Nike, Kimberly-Clark, and Conagra Brands
- Nike's Price Plunge: Nike's stock has fallen nearly 70% over the past five years, currently trading at $43.49 with a market cap of $63 billion, facing significant headwinds from foreign competition, the rise of fast fashion, and inflation; despite efforts by the new CEO to focus on in-store sales, results have been disappointing, leaving future growth uncertain.
- Kimberly-Clark's Acquisition Concerns: Kimberly-Clark's shares have dropped over 30% in five years, now priced at $96.05 with a market cap of $31 billion; the announcement of a nearly $49 billion acquisition of Kenvue has rattled investors, as it could enhance its position in global health and wellness but also increases risk significantly.
- Conagra Brands' Major Challenges: Conagra's stock has declined nearly 60% in five years, currently at $15.56 with a market cap of $7.4 billion, struggling with growth due to factors like GLP-1 drugs reducing consumer appetites, rising food costs, and high oil prices, leading to a 1.9% drop in Q3 sales, casting a shadow over future prospects.
- Sustainability of High Dividend: Conagra offers a high dividend yield of 9.04%, but concerns about its sustainability arise due to low margins; while its forward P/E ratio is under nine, indicating attractive valuation, the lack of growth potential makes it a risky investment choice.
See More
Nike, Kimberly-Clark, and Conagra Stocks Plummet Over 30%
- Nike's Stock Plunge: Nike's share price has fallen nearly 70% over the past five years, reaching its lowest point since 2014, primarily due to rising international competition, the popularity of fast fashion, and inflation, which have created significant growth challenges for the company.
- Kimberly-Clark's Acquisition Concerns: Kimberly-Clark's stock has dropped over 30% in five years, with its announcement of a nearly $49 billion acquisition of Kenvue rattling investors; while this deal could enhance its position in the global health and wellness sector, it also increases the risk associated with what was previously considered a stable investment.
- Conagra Brands' Struggles: Conagra's shares have declined nearly 60% over five years, hitting levels not seen since 2009, largely due to the impact of GLP-1 drugs on consumer appetites, rising food costs, and elevated oil prices, all contributing to the company's inability to generate growth.
- Dividend Sustainability in Question: Despite Conagra's high dividend yield of around 9%, concerns about the sustainability of this payout are growing due to light margins, leading investors to speculate that a dividend cut may be inevitable, which could further undermine investor confidence.
See More
Johnson & Johnson Stock Supported by Strong Financials
- Strong Financial Performance: Johnson & Johnson reported revenue of $94.2 billion in 2025, a 6% increase, with earnings per share (EPS) reaching $11.03, up 90.5%, reflecting significant profitability improvement post-Kenvue spinoff.
- Consistent Dividend Growth: The company has raised its dividend for 63 consecutive years, with the latest 4.8% increase bringing the quarterly payout to $1.30 per share, resulting in a current yield of approximately 2.1%, bolstering investor confidence in its stock.
- Leading R&D Investment: Johnson & Johnson invested $14.6 billion in research and development last year, achieving 51 drug approvals and launching 15 new med-tech products, underscoring its leadership and innovation in the pharmaceutical sector.
- Existing Risks: Despite strong financials, Johnson & Johnson faces tens of thousands of lawsuits and pricing pressures from the Inflation Reduction Act, which could impact its future profit margins.
See More
